Viverita Discovery

Cancer remains a deadly disease with tremendous unmet medical needs and the shortage of effective therapeutic targets continues to be a key limitation in developing life-saving cancer treatments.

ViVerita Discovery FlexCo, together with the parent company ViVerita Therapeutics Inc. (headquartered in Boston, USA), are committed to identifying and de-risking novel drug targets and discovering a new wave of precision cancer therapies by embracing the complexity and heterogeneity of cancer. We believe that truth hides in vivo (i.e. In Vivo Veritas). Our proprietary in vivo discovery platform includes transformative genetic screening technologies and faithful disease models to uniquely position us to unveil a big wave of physiologically relevant novel targets and biomarkers to empower the development of novel precision cancer therapies.